Trusted Second Opinion Partner - Cromwell Hospital

Datar Cancer Genetics - UK

Monitor

cancer or its recurrence or changes

in the tumor characteristics through
a simple blood test….

Keeping track of cancer is very critical

Cancer is best managed by a treatment plan that stays one step ahead of the tumor. Conventional techniques such as imaging or scans could take more than 3 months to detect the effectiveness of treatments. It is important to determine as quickly as possible if the cancer is responding to the therapy or is progressing.

Cancertrack is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. Cancertrack can be used to monitor the disease / recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anaesthesia or painful surgical biopsies.

Features of CancertrackTM

  • Multi-coordinate and multi-dimensional probes to track down DNA and RNA eleased by cancer cells in the patient’s blood
  • Unique, unprecedented capability to detect cancerous activity
  • Enables real-time, rapid response to the dynamic molecular profile of a patient’s cancer
  • Safe, accurate, simple, and cost-effective
  • Non-invasive blood test
  • Not dependent on the availability of tissue
  • Tests all active disease sites
  • Limit of detection is 0.1% Mutal Allele Frequency
  • For more powerful than conventional biopsy
  • Extensive coverage of NCCN recommended biomarkers

Features of Cancertrack™

    • Multi-coordinate and multi-dimensional probes to track down DNA and RNA released by cancer cells in the patient’s blood
    • Unique, unprecedented capability to detect cancerous activity
    • Enables real-time, rapid response to the dynamic molecular profile of a patient’s cancer
    • Safe, accurate, simple, and cost-effective
    • Non-invasive blood test
    • Not dependent on the availability of tissue
    • Tests all active disease sites
    • Limit of detection is 0.1% Mutal Allele Frequency
    • For more powerful than conventional biopsy
    • Extensive coverage of NCCN recommended biomarkers

Cancertrack is suitable for

Every person who has been diagnosed with cancer; as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumor DNA and RNA before the initiation of therapy.

Every patient who is in remission or a cancer survivor and needs monitoring

Every patient who is under treatment for cancer

Every patient in whom the cancer is not responding satisfactorily to 'Standard of Care' therapy

We’re here to assist you

If you have any questions or want to learn more, please contact us or visit our FAQs.

We're Here to Help

Thank you for your interest in our test. We request you to confirm your email address before we proceed. Kindly fill-up the form and send, to receive the brochure by email.

Cancertrack_Brochure

Get second opinion now

Please contact on:
+44 (0)20 7460 5586
[email protected]

OR